{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"153"}]}],"title":">=1 adverse event (AE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"107"}]}],"title":">=1 CTCAE grade 3-4 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}],"title":">=1 CTCAE grade 5 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"56"}]}],"title":">=1 serious AE (SAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"145"},{"groupId":"OG002","value":"131"}]}],"title":">=1 AE related to Lenaldomide/Placebo"},{"categories":[{"measurements":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"134"},{"groupId":"OG002","value":"126"}]}],"title":">=1 AE related to Melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"93"}]}],"title":">=1AE related to Prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"117"},{"groupId":"OG002","value":"68"}]}],"title":">=1 Grade 3-4 AE related to Lenaldomide/Placebo"},{"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"62"}]}],"title":">=1 Grade 3-4 AE related to Melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"22"}]}],"title":">=1 Grade 3-4 AE related to Prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":">=1 Grade 5 AE related to Lenalidomide/Placebo"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":">=1 Grade 5 AE related to Melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}],"title":">=1 Grade 5 AE related to Prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"11"}]}],"title":">=1 SAE related to Lenalidomide/Placebo"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"11"}]}],"title":">=1 SAE related to Melphalan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"5"}]}],"title":">=1 SAE related to Prednisone"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"14"}]}],"title":">=1 AE leading to Lenalidomide/Placebo withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"}]}],"title":">=1 AE leading to Melphalan withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"}]}],"title":">=1 AE leading to Prednisone withdrawal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"26"}]}],"title":">=1 AE leading to Lenalidomide/Plac dose reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"21"}]}],"title":">=1 AE leading to Melphalan dose reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}],"title":">=1 AE leading to Prednisone dose reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"82"},{"groupId":"OG002","value":"51"}]}],"title":">=1 AE leading to Lenalidomide/Plac dose interrupt"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"title":">=1 AE leading to Melphalan dose interruption"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"15"}]}],"title":">=1 AE leading to Prednisone dose interruption"}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"153"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"NUMBER","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Up to 169 weeks (Double-blind therapy period plus 4 weeks)","title":"Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period","type":"SECONDARY","unitOfMeasure":"participants"}